Martin joined Boehringer Ingelheim Venture Fund (BIVF) in 2010 and established US offices for BIVF in 2013 in Cambridge, MA. His focus is on early biotechnology startups in the United States. He has built and launched several successful biotech companies. Prior to joining BIVF, Martin held several Marketing positions at Solvay Pharmaceuticals and Boehringer Ingelheim Pharmaceuticals in CNS and Oncology and was involved in the launch of various drugs in the CNS space. Martin started his career as investment professional by joining BayernKapital in 2002 to focus on seed investments in biotechnology companies. Martin holds a PhD in Biology from University at Würzburg and an MBA from University Hagen. Martin currently serves on the Boards of Armagen Inc., Sentien Biotech, Rgenta Therapeutics, and Abexxa Biologics.